{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T20:18:32Z","timestamp":1648930712121},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clinthera.2016.08.011","type":"journal-article","created":{"date-parts":[[2016,9,24]],"date-time":"2016-09-24T08:04:43Z","timestamp":1474704283000},"page":"2196-2203.e5","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of CHA2DS2VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multi-payer Analysis"],"prefix":"10.1016","volume":"38","author":[{"given":"Aarti A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie W.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Schein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.08.011_bib1","doi-asserted-by":"crossref","unstructured":"Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 200;285:2370\u20132375.","DOI":"10.1001\/jama.285.18.2370"},{"key":"10.1016\/j.clinthera.2016.08.011_bib2","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2016.08.011_bib3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/europace\/eut244","article-title":"Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients","volume":"16","author":"Winkle","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2016.08.011_bib4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2016.08.011_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ejvs.2014.05.001","article-title":"Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials","volume":"48","author":"Kakkos","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.clinthera.2016.08.011_bib6","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.08.011_bib7","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/01.STR.0000230607.07928.17","article-title":"Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002)","volume":"37","author":"Lakshminarayan","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2016.08.011_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","article-title":"Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis","volume":"156","author":"Goto","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2016.08.011_bib9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.08.011_bib10","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.amjmed.2009.11.015","article-title":"Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?","volume":"123","author":"Zimetbaum","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.08.011_bib11","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2016.08.011_bib12","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2016.08.011_bib13","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.08.011_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2016.08.011_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/cer.15.48","article-title":"Antithrombotic use and bleeding risk in patients with atrial fibrillation: findings from a multipayer analysis","volume":"5","author":"Lang","year":"2016","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.clinthera.2016.08.011_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2369-13-145","article-title":"Outpatient red blood cell transfusion payments among patients on chronic dialysis","volume":"13","author":"Gitlin","year":"2012","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2016.08.011_bib17","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.urology.2012.08.008","article-title":"Timing of orchiopexy in the United States: a quality-of-care indicator","volume":"80","author":"Yiee","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.clinthera.2016.08.011_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2016.08.011_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/jamainternmed.2015.13","article-title":"Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation","volume":"175","author":"O\u2019Brien","year":"2015","journal-title":"JAMA Intern Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816306580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816306580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T00:53:19Z","timestamp":1536367999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816306580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0149291816306580"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of CHA2DS2VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multi-payer Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}